Toronto General Hospital Research Institute, University Health Network, Toronto, ON M5G 1L7, Canada.
Department of Laboratory Medicine and Pathobiology, University of Toronto, Toronto, ON M5S 1A8, Canada.
Int J Mol Sci. 2021 Apr 27;22(9):4590. doi: 10.3390/ijms22094590.
With recent clinical breakthroughs, immunotherapy has become the fourth pillar of cancer treatment. Particularly, immune cell-based therapies have been envisioned as a promising treatment option with curative potential for leukemia patients. Hence, an increasing number of preclinical and clinical studies focus on various approaches of immune cell-based therapy for treatment of acute leukemia (AL). However, the use of different immune cell lineages and subsets against different types of leukemia and patient disease statuses challenge the interpretation of the clinical applicability and outcome of immune cell-based therapies. This review aims to provide an overview on recent approaches using various immune cell-based therapies against acute B-, T-, and myeloid leukemias. Further, the apparent limitations observed and potential approaches to overcome these limitations are discussed.
随着最近的临床突破，免疫疗法已成为癌症治疗的第四大支柱。特别是，免疫细胞疗法被认为是一种有前途的治疗选择，有可能治愈白血病患者。因此，越来越多的临床前和临床试验集中在各种免疫细胞疗法治疗急性白血病（AL）的方法上。然而，针对不同类型的白血病和患者疾病状态使用不同的免疫细胞谱系和亚群，对免疫细胞疗法的临床适用性和结果的解释提出了挑战。本综述旨在概述使用各种免疫细胞疗法治疗急性 B 细胞、T 细胞和髓性白血病的最新方法。此外，还讨论了观察到的明显局限性以及克服这些局限性的潜在方法。
